Stockscreener 앱 받기
10.18
5.57%
-0.60
시간 외 거래:
10.48
0.30
+2.95%
전일 마감가:
$10.78
열려 있는:
$10.38
하루 거래량:
280.27K
Relative Volume:
0.80
시가총액:
$62.26M
수익:
$55.54M
순이익/손실:
$-180.40M
주가수익비율:
-12.92
EPS:
-0.7877
순현금흐름:
$-170.32M
1주 성능:
-14.09%
1개월 성능:
-27.41%
6개월 성능:
-61.40%
1년 성능:
-94.91%
1일 변동 폭
$9.7744
$10.66
1주일 범위
$9.7744
$12.14
52주 변동 폭
$9.104
$309.60
Gossamer Bio Inc Stock (GOSS) Company Profile
명칭
Gossamer Bio Inc
전화
(858) 684-1300
주소
3115 MERRYFIELD ROW, SAN DIEGO, CA
Compare GOSS vs VRTX, MRNA, REGN, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GOSS
Gossamer Bio Inc
|
10.18 | 66.91M | 55.54M | -180.40M | -170.32M | -0.7877 |
VRTX
Vertex Pharmaceuticals Inc
|
505.64 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
196.48 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
742.12 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
928.44 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
200.87 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-23 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2026-02-24 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2026-02-24 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2026-02-24 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2026-01-28 | 개시 | Barclays | Overweight |
| 2025-09-10 | 업그레이드 | UBS | Neutral → Buy |
| 2025-07-14 | 개시 | Scotiabank | Sector Outperform |
| 2024-06-25 | 개시 | Oppenheimer | Outperform |
| 2024-04-05 | 재개 | Wedbush | Outperform |
| 2023-07-27 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-03-07 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2023-03-01 | 개시 | Guggenheim | Neutral |
| 2022-12-07 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2022-12-07 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-12-07 | 다운그레이드 | SMBC Nikko | Outperform → Neutral |
| 2022-10-20 | 개시 | Goldman | Buy |
| 2022-09-21 | 개시 | JP Morgan | Neutral |
| 2022-09-19 | 개시 | Wedbush | Outperform |
| 2022-04-18 | 개시 | Raymond James | Outperform |
| 2022-04-06 | 개시 | UBS | Buy |
| 2022-01-10 | 업그레이드 | SMBC Nikko | Neutral → Outperform |
| 2021-11-09 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-09-21 | 재개 | Piper Sandler | Overweight |
| 2020-06-29 | 개시 | H.C. Wainwright | Buy |
| 2020-04-22 | 개시 | Piper Sandler | Overweight |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2019-12-03 | 재개 | BofA/Merrill | Buy |
| 2019-10-30 | 개시 | Berenberg | Buy |
| 2019-03-05 | 개시 | Barclays | Overweight |
| 2019-03-05 | 개시 | BofA/Merrill | Buy |
| 2019-03-05 | 개시 | Evercore ISI | Outperform |
| 2019-03-05 | 개시 | SVB Leerink | Outperform |
모두보기
Gossamer Bio Inc 주식(GOSS)의 최신 뉴스
Gossamer Bio Inc (GOSS) Stock Price Target & Forecast - TradingKey
A shareholder falls below 5% in Gossamer Bio (GOSS) after a reverse stock split. - Stock Titan
Gossamer Bio regains Nasdaq compliance after 1-for-80 reverse stock split - TradingView
Form 4 Gossamer Bio Inc For: 25 September By Investing.com - Investing.com Nigeria
GOSSAMER BIO INC (GOSS) Stock Chart - ChartMill
At $10.99 a share, Gossamer Bio (GOSS) director Sandra Milligan receives a stock option. - Stock Titan
At Gossamer Bio (GOSS), director Daniel Thomas O's options carry a $10.99 exercise price. - Stock Titan
Gossamer Bio (GOSS) grants a director options priced at $10.99 per share - Stock Titan
At Gossamer Bio (GOSS), director Drynan Skye receives stock options priced at $10.99 per share. - Stock Titan
Director Russell J. Cox receives Gossamer Bio (GOSS) options with a $10.99-per-share exercise price. - Stock Titan
Gossamer Bio grants director options on 10,000 shares - Stock Titan
Gossamer Bio stock falls 5.99 percent after FDA filing - AD HOC NEWS
Gossamer Bio submits seralutinib NDA after Phase 3 endpoint miss - Mugglehead Investment Magazine
Gossamer Bio Submits First NDA for Seralutinib to FDA for Pulmonary Arterial Hypertension - Kalkine Media
Gossamer Bio (GOSS) Files NDA for Seralutinib Amidst Challenging Valuation Landscape - GuruFocus
Gossamer Bio submits NDA for seralutinib for pulmonary arterial hypertension - TradingView
Gossamer Bio stock rises on FDA filing for PAH drug - Investing.com India
Gossamer Bio Files New Drug Application for Seralutinib - Yahoo Finance
Gossamer Bio Submits New Drug Application To US FDA For Seralutinib For The Treatment Of Pulmonary Arterial Hypertension - TradingView
Gossamer Bio stock rises on FDA filing for PAH drug By Investing.com - Investing.com Nigeria
Gossamer Bio submits NDA for seralutinib in PAH treatment By Investing.com - Investing.com Australia
Gossamer Bio (GOSS) Files NDA for Seralutinib Amid Low Valuation and Mixed Financial Signals - GuruFocus
Gossamer Bio submits NDA for seralutinib in PAH treatment - Investing.com
Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension - Yahoo Finance
Gossamer Bio : Initial Statement of Beneficial Ownership (Form 3) - marketscreener.com
Gossamer Bio stock gains 12.04 percent in the latest quote - AD HOC NEWS
Equity in earnings of Gossamer Bio, Inc. – SWB:4GB0 - TradingView
Total assets of Gossamer Bio, Inc. – SWB:4GB0 - TradingView
GOSS Maintained by HC Wainwright & Co. -- Price Target Raised to $90 - GuruFocus
GOSS Price Target Soars to $90 After Reverse Split; Market Prici - GuruFocus
H.C. Wainwright Maintains Gossamer Bio(GOSS.US) With Buy Rating, Cuts Target Price to $90 - Moomoo
HC Wainwright & Co. maintains Buy rating on Gossamer Bio, $90 price target - TradingView
Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash? - Stocktwits
Cash flow from financing activities of Gossamer Bio, Inc. – MUN:4GB0 - TradingView
GOSS News | GOSSAMER BIO INC (NASDAQ:GOSS) - ChartMill
Gossamer Bio Adds Veteran Investor to Board of Directors - The Globe and Mail
Gossamer Bio (NASDAQ: GOSS) Schedules October 27 Vote on Warrants and Preferred Stock Conversion - kalkinemedia.com
Cash flow from financing activities of Gossamer Bio, Inc. – LSX:A42M0V - TradingView
Total assets of Gossamer Bio, Inc. – LSX:A42M0V - TradingView
Gossamer Bio appoints Greg Ciongoli to board of directors By Investing.com - Investing.com Nigeria
Gossamer Bio appoints Greg Ciongoli to board of directors - Investing.com
Gossamer Bio, Inc. Announces Appointment of Greg Ciongoli to Board of Directors and Audit Committee, Effective September 16, 2026 - marketscreener.com
Gossamer Bio Appoints Greg Ciongoli to Board of Directors - Yahoo Finance
Gossamer Bio Inc to discuss its business update Transcript - GuruFocus
Gossamer Bio Inc (FRA:4GB0) Stock Price & 30 Year Financial Data - GuruFocus
Gossamer Bio (FRA:4GB0) PensionAndRetirementBenefit : €0.00 Mil (As of Jun. 2026) - GuruFocus
Gossamer Bio (FRA:4GB0) Net Issuance of Debt : €0.00 Mil (TTM As of Jun. 2026) - GuruFocus
Gossamer Bio Inc (FRA:4GB0) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Form 8K Gossamer Bio Inc For: 11 September By Investing.com - Investing.com Nigeria
Gossamer Bio completes 1-for-80 reverse stock split By Investing.com - Investing.com Australia
Gossamer Bio Implements 1-for-80 Reverse Stock Split to Address Nasdaq Compliance - citybiz
Gossamer Bio Inc (GOSS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.50%
0.57%
자본화:
|
볼륨(24시간):